SEC Comment Letter for Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Jan 3, 2018
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Jan. 3, 2018 · CIK: 0001671502 · Accession: 0000000000-18-000249
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 3030 January 3, 2018 Via E -mail Dr. Shai Yarkoni Chief Executive Officer Cellect Biotechnology Ltd. 23 Hata’as Street Kfar Saba, Israel 44425
Re: Cellect Biotechnology Ltd. Registration Statement on Form F-1 Filed December 28, 2017 File No. 333 -222334
Dear Dr. Yarkoni :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tom Jones at (202) 551 -3602 with any questions.
Sincerely,
/s/ Tom Jones for
Show Raw Text
Mail Stop 3030
January 3, 2018
Via E -mail
Dr. Shai Yarkoni
Chief Executive Officer
Cellect Biotechnology Ltd.
23 Hata’as Street
Kfar Saba, Israel 44425
Re: Cellect Biotechnology Ltd.
Registration Statement on Form F-1
Filed December 28, 2017
File No. 333 -222334
Dear Dr. Yarkoni :
This is to advise you that we have not reviewed and will not review your registration
statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tom Jones at (202) 551 -3602 with any questions.
Sincerely,
/s/ Tom Jones for
Amanda Ravitz
Assistant Director
Office of Electronics and Machinery
cc: Ronen Kantor, Esq.